Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
Chromosome | X | Map location | Xq28 | dbXrefs | |
Description | cancer/testis antigen 1B |
GTO ID | GTC0285 |
Trial ID | NCT02650986 |
Disease | Fallopian Tube Cancer | Melanoma | Ovarian Carcinoma | Synovial Sarcoma | Peritoneal Carcinoma |
Altered gene | NY-ESO-1 |
Therapeutic/Target gene | Target gene |
Therapy | TCR-T cell |
Treatment | NY-ESO-1 TCR-T cells |
HLA | HLA-A*02:01 |
Phase | Phase1|Phase2 |
Recruitment status | Active, Not Recruiting |
Title | A Phase I/IIa Study of TGFβ Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies |
Year | 2015 |
Country | United States |
Company sponsor | Roswell Park Cancer Institute |
Other ID(s) | I 258514|NCI-2015-02080|I 258514|P30CA016056|R01CA164333 |
Cohort1: dose level 1 | |||||||||||||||
|
|||||||||||||||
Cohort2: dose level 2 | |||||||||||||||
|